RxDoctor Payments Data

Karina Mercado

Physician Assistant · San Antonio, TXNPI 1477006393

Payments from drug & device makers

$7,416in general payments, 2019–2025

Across 362 payments — averaging $20.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Medtronic$1K
  • Amgen$496
  • Dexcom, Inc.$482
  • Lilly USA, LLC$383
  • AbbVie$333
  • plus $3K from 35 others

What the payments were for

  • Travel & lodging$1,04814%
  • Food & beverage$6,34286%
  • Education$260%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,416 in reported general payments places this provider in the 90th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$3,500
Medicare patients
15
Services billed
63

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide40$54,690
Tresiba Flextouch U-200Insulin Degludec11$17,861
FarxigaDapagliflozin Propanediol12$15,460
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog15$13,840
Breo ElliptaFluticasone/Vilanterol17$11,968
Tresiba Flextouch U-100Insulin Degludec17$7,657
Repatha SureclickEvolocumab13$7,003
Novolog FlexpenInsulin Aspart15$4,244
Insulin Lispro Kwikpen U-100Insulin Lispro14$1,745
Rosuvastatin Calcium158$1,633
Humalog Kwikpen U-100Insulin Lispro12$1,299
Levothyroxine Sodium122$1,224
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$1,197
Atorvastatin Calcium143$879
Albuterol Sulfate HfaAlbuterol Sulfate20$877

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,794$54,69040 claims
AstraZenecaFarxiga$272$15,46012 claims
GSKBreo Ellipta$132$11,96817 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$63$1,224122 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →